The manufacturing process for napabucasin described herein
produced
drug substance reliably on a scale up to 100 kg. The purification
strategy employed was effective at removing process-related impurities
and consistently afforded drug substance that met specifications.
Below, we present an overview of the process development history and
the impurity control strategy that was implemented to achieve robust
manufacturing performance. Critical process parameters were identified,
and process-related impurities and their proposed mechanisms of formation
are presented.